Low level of hepatitis b virus screening among patients receiving chemotherapy

Chung Il Wi, Nicole M. Loo, Joseph J. Larson, Timothy J. Moynihan, Nageswar R. Madde, Darryl C. Grendahl, Steven Robert Alberts, W. Ray Kim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background & Aims: Chemotherapy of patients with inactive hepatitis B virus (HBV) infection can lead to viral reactivation and hepatitis flares. We investigated the proportion of patients screened for HBV infection before chemotherapy over time and the outcomes of screened patients. Methods: In a retrospective study, we collected data from a pharmacy database on patients who underwent cytotoxic chemotherapy for solid or hematologic malignancies at the Mayo Clinic in Rochester, Minnesota, from January 1, 2006, through September 30, 2011. Laboratory data were collected from electronic medical records. Screening was identified based on tests for hepatitis B surface antigen, for any reason at any time before chemotherapy. Results: Of 8005 patients undergoing chemotherapy, 1279 (16%) were screened for HBV infection before chemotherapy, including 668 of 1805 patients with hematologic malignancies (37%). The proportion of patients screened for HBV increased from 14.3% in 2006 to 2008 to 17.7% in 2009 to 2011 (P < .01). This trend was attributed mostly to an increase in the proportion of patients with hematologic malignancies, from 32.7% in 2006 to 2008 to 40.6% in 2009 to 2011 (P < .01). Of 13 patients who tested positive for HBV, 5 did not receive prophylactic antiviral therapy; HBV infection was reactivated in 2 of these patients. None of the 8 patients who received an antiviral agent before chemotherapy experienced HBV reactivation. Of 58 unscreened patients who had increases in their alanine aminotransferase level (>300 U/L), only 1 patient appeared to have an undiagnosed HBV infection. Conclusions: Only a small percentage of patients receiving chemotherapy are screened for HBV infection. However, a larger proportion of patients was screened during 2009 to 2011 than during 2006 to 2008, especially patients with hematologic malignancies. Strategies are needed to ensure that patients receiving chemotherapy are protected from the consequences of undiagnosed HBV infection.

Original languageEnglish (US)
Pages (from-to)970-975
Number of pages6
JournalClinical Gastroenterology and Hepatology
Volume13
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Hepatitis Viruses
Drug Therapy
Hepatitis B virus
Virus Diseases
Hematologic Neoplasms
Electronic Health Records
Hepatitis B Surface Antigens
Hepatitis
Retrospective Studies

Keywords

  • Abnormal liver enzyme
  • Preemptive antiviral
  • Risk factor
  • Universal screening

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Wi, C. I., Loo, N. M., Larson, J. J., Moynihan, T. J., Madde, N. R., Grendahl, D. C., ... Kim, W. R. (2015). Low level of hepatitis b virus screening among patients receiving chemotherapy. Clinical Gastroenterology and Hepatology, 13(5), 970-975. https://doi.org/10.1016/j.cgh.2014.10.032

Low level of hepatitis b virus screening among patients receiving chemotherapy. / Wi, Chung Il; Loo, Nicole M.; Larson, Joseph J.; Moynihan, Timothy J.; Madde, Nageswar R.; Grendahl, Darryl C.; Alberts, Steven Robert; Kim, W. Ray.

In: Clinical Gastroenterology and Hepatology, Vol. 13, No. 5, 01.05.2015, p. 970-975.

Research output: Contribution to journalArticle

Wi, CI, Loo, NM, Larson, JJ, Moynihan, TJ, Madde, NR, Grendahl, DC, Alberts, SR & Kim, WR 2015, 'Low level of hepatitis b virus screening among patients receiving chemotherapy', Clinical Gastroenterology and Hepatology, vol. 13, no. 5, pp. 970-975. https://doi.org/10.1016/j.cgh.2014.10.032
Wi, Chung Il ; Loo, Nicole M. ; Larson, Joseph J. ; Moynihan, Timothy J. ; Madde, Nageswar R. ; Grendahl, Darryl C. ; Alberts, Steven Robert ; Kim, W. Ray. / Low level of hepatitis b virus screening among patients receiving chemotherapy. In: Clinical Gastroenterology and Hepatology. 2015 ; Vol. 13, No. 5. pp. 970-975.
@article{c0f47c1c208a495098f88cdca30a0e12,
title = "Low level of hepatitis b virus screening among patients receiving chemotherapy",
abstract = "Background & Aims: Chemotherapy of patients with inactive hepatitis B virus (HBV) infection can lead to viral reactivation and hepatitis flares. We investigated the proportion of patients screened for HBV infection before chemotherapy over time and the outcomes of screened patients. Methods: In a retrospective study, we collected data from a pharmacy database on patients who underwent cytotoxic chemotherapy for solid or hematologic malignancies at the Mayo Clinic in Rochester, Minnesota, from January 1, 2006, through September 30, 2011. Laboratory data were collected from electronic medical records. Screening was identified based on tests for hepatitis B surface antigen, for any reason at any time before chemotherapy. Results: Of 8005 patients undergoing chemotherapy, 1279 (16{\%}) were screened for HBV infection before chemotherapy, including 668 of 1805 patients with hematologic malignancies (37{\%}). The proportion of patients screened for HBV increased from 14.3{\%} in 2006 to 2008 to 17.7{\%} in 2009 to 2011 (P < .01). This trend was attributed mostly to an increase in the proportion of patients with hematologic malignancies, from 32.7{\%} in 2006 to 2008 to 40.6{\%} in 2009 to 2011 (P < .01). Of 13 patients who tested positive for HBV, 5 did not receive prophylactic antiviral therapy; HBV infection was reactivated in 2 of these patients. None of the 8 patients who received an antiviral agent before chemotherapy experienced HBV reactivation. Of 58 unscreened patients who had increases in their alanine aminotransferase level (>300 U/L), only 1 patient appeared to have an undiagnosed HBV infection. Conclusions: Only a small percentage of patients receiving chemotherapy are screened for HBV infection. However, a larger proportion of patients was screened during 2009 to 2011 than during 2006 to 2008, especially patients with hematologic malignancies. Strategies are needed to ensure that patients receiving chemotherapy are protected from the consequences of undiagnosed HBV infection.",
keywords = "Abnormal liver enzyme, Preemptive antiviral, Risk factor, Universal screening",
author = "Wi, {Chung Il} and Loo, {Nicole M.} and Larson, {Joseph J.} and Moynihan, {Timothy J.} and Madde, {Nageswar R.} and Grendahl, {Darryl C.} and Alberts, {Steven Robert} and Kim, {W. Ray}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.cgh.2014.10.032",
language = "English (US)",
volume = "13",
pages = "970--975",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Low level of hepatitis b virus screening among patients receiving chemotherapy

AU - Wi, Chung Il

AU - Loo, Nicole M.

AU - Larson, Joseph J.

AU - Moynihan, Timothy J.

AU - Madde, Nageswar R.

AU - Grendahl, Darryl C.

AU - Alberts, Steven Robert

AU - Kim, W. Ray

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background & Aims: Chemotherapy of patients with inactive hepatitis B virus (HBV) infection can lead to viral reactivation and hepatitis flares. We investigated the proportion of patients screened for HBV infection before chemotherapy over time and the outcomes of screened patients. Methods: In a retrospective study, we collected data from a pharmacy database on patients who underwent cytotoxic chemotherapy for solid or hematologic malignancies at the Mayo Clinic in Rochester, Minnesota, from January 1, 2006, through September 30, 2011. Laboratory data were collected from electronic medical records. Screening was identified based on tests for hepatitis B surface antigen, for any reason at any time before chemotherapy. Results: Of 8005 patients undergoing chemotherapy, 1279 (16%) were screened for HBV infection before chemotherapy, including 668 of 1805 patients with hematologic malignancies (37%). The proportion of patients screened for HBV increased from 14.3% in 2006 to 2008 to 17.7% in 2009 to 2011 (P < .01). This trend was attributed mostly to an increase in the proportion of patients with hematologic malignancies, from 32.7% in 2006 to 2008 to 40.6% in 2009 to 2011 (P < .01). Of 13 patients who tested positive for HBV, 5 did not receive prophylactic antiviral therapy; HBV infection was reactivated in 2 of these patients. None of the 8 patients who received an antiviral agent before chemotherapy experienced HBV reactivation. Of 58 unscreened patients who had increases in their alanine aminotransferase level (>300 U/L), only 1 patient appeared to have an undiagnosed HBV infection. Conclusions: Only a small percentage of patients receiving chemotherapy are screened for HBV infection. However, a larger proportion of patients was screened during 2009 to 2011 than during 2006 to 2008, especially patients with hematologic malignancies. Strategies are needed to ensure that patients receiving chemotherapy are protected from the consequences of undiagnosed HBV infection.

AB - Background & Aims: Chemotherapy of patients with inactive hepatitis B virus (HBV) infection can lead to viral reactivation and hepatitis flares. We investigated the proportion of patients screened for HBV infection before chemotherapy over time and the outcomes of screened patients. Methods: In a retrospective study, we collected data from a pharmacy database on patients who underwent cytotoxic chemotherapy for solid or hematologic malignancies at the Mayo Clinic in Rochester, Minnesota, from January 1, 2006, through September 30, 2011. Laboratory data were collected from electronic medical records. Screening was identified based on tests for hepatitis B surface antigen, for any reason at any time before chemotherapy. Results: Of 8005 patients undergoing chemotherapy, 1279 (16%) were screened for HBV infection before chemotherapy, including 668 of 1805 patients with hematologic malignancies (37%). The proportion of patients screened for HBV increased from 14.3% in 2006 to 2008 to 17.7% in 2009 to 2011 (P < .01). This trend was attributed mostly to an increase in the proportion of patients with hematologic malignancies, from 32.7% in 2006 to 2008 to 40.6% in 2009 to 2011 (P < .01). Of 13 patients who tested positive for HBV, 5 did not receive prophylactic antiviral therapy; HBV infection was reactivated in 2 of these patients. None of the 8 patients who received an antiviral agent before chemotherapy experienced HBV reactivation. Of 58 unscreened patients who had increases in their alanine aminotransferase level (>300 U/L), only 1 patient appeared to have an undiagnosed HBV infection. Conclusions: Only a small percentage of patients receiving chemotherapy are screened for HBV infection. However, a larger proportion of patients was screened during 2009 to 2011 than during 2006 to 2008, especially patients with hematologic malignancies. Strategies are needed to ensure that patients receiving chemotherapy are protected from the consequences of undiagnosed HBV infection.

KW - Abnormal liver enzyme

KW - Preemptive antiviral

KW - Risk factor

KW - Universal screening

UR - http://www.scopus.com/inward/record.url?scp=84927910917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927910917&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2014.10.032

DO - 10.1016/j.cgh.2014.10.032

M3 - Article

C2 - 25460017

AN - SCOPUS:84927910917

VL - 13

SP - 970

EP - 975

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 5

ER -